Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 26Pain, Postoperative 17Neoplasms 13Lung Neoplasms 12Brain Neoplasms 12Depression 7Carcinoma, Hepatocellular 7Pain 6Colonic Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Prostatic Neoplasms 5Leiomyoma 5Head and Neck Neoplasms 5Agnosia 5Ovarian Neoplasms 4Multiple Myeloma 4Delirium 4Colorectal Neoplasms 4Anxiety Disorders 4Supratentorial Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Myofibroma 3Lymphoma 3Hemorrhage 3Fatigue 3Emergence Delirium 3Chronic Pain 3Carcinoma, Non-Small-Cell Lung 3

Interventions

fluorodopa F 18 4Temozolomide 2Leucovorin 2Fluorouracil 2Everolimus 2Capecitabine 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1vatalanib 1regorafenib 1pentetreotide 1pasireotide 1Thalidomide 1Surgical Procedures, Operative 1Solutions 1Saline Solution 1Panobinostat 1Oxaliplatin 1Octreotide 1Observation 1Irinotecan 1Injections 1High-Energy Shock Waves 1Doxorubicin 1Bortezomib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Insulinoma × Saline Solution × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡